Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of Vietnam

Malaria Journal

Volumn 16, Issue 1, 2017, Pages 1-10

  Thanh, Ngo Viet ^a   Thuy Nhien, Nguyen ^a   Tuyen, Nguyen Thi Kim ^a   Tong, Nguyen Thanh ^a   Nha Ca, Nguyen Thuy ^a   Dong, Le Thanh ^b   Quang, Huynh Hong ^b   Farrar, Jeremy ^a,c   Thwaites, Guy ^a,c   White, Nicholas J ^c,d   Wolbers, Marcel ^a,c   Hien, Tran Tinh ^a,c  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b Institute of Malariology Parasitology and Entomology   (Viet Nam)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Artemisinin resistance; Parasite clearance half life; Piperaquine resistance

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; DIHYDROARTEMISININ PLUS PIPERAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; PIPERAQUINE; QUINOLINE DERIVATIVE;

ADOLESCENT; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENETIC POLYMORPHISM; GENETIC RESISTANCE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; NONHUMAN; PARASITE CLEARANCE; PLASMODIUM FALCIPARUM; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; VIET NAM; ADULT; DRUG EFFECTS; DRUG RESISTANCE; ENDEMIC DISEASE; INCIDENCE; ISOLATION AND PURIFICATION; MALARIA, FALCIPARUM; PARASITOLOGY; PRESCHOOL CHILD; TIME FACTOR; TREATMENT FAILURE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; ENDEMIC DISEASES; FEMALE; HUMANS; INCIDENCE; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; QUINOLINES; TIME FACTORS; TREATMENT FAILURE; VIETNAM; YOUNG ADULT;

EID: 85010282372     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-017-1680-8     Document Type: Article

References (24)

1. National Institute of Malariology Parasitology and Entomology. Report of National institute of malariology parasitology and entomology, 2015.
2. WHO. World malaria report 2014. Geneva: World Health Organization; 2014.
3. Ménard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, et al. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med. 2016;374:2453-64.
4. WHO. Global plan for artemisinin resistance containment. Geneva: World Health Organization; 2011.
5. WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009.
6. Ministry of Health Portal VietNam. 2009. Guidelines for malaria diagnosis and treatment in VietNam.
7. WHO. Methods and techniques for clinical trial on antimalarial drug efficacy : genotyping to identify parasite populations. Geneva: World Health Organization; 2007.
8. Shannon T-H, Clark TG, Jacob CG, Cummings MP, Miotto O, Dondorp AM, et al. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci USA. 2013;110:240-5.
9. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50-5.
10. Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in vitro and ex vivo drug-response studies. Lancet Infect Dis. 2013;13:1043-9.
11. Duru V, Khim N, Leang R, Kim S, Domergue A, Kloeung N, et al. Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations. BMC Med. 2015;13:305.
12. Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, et al. Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. Lancet Infect Dis. 2016; pii S1473-3099 (Epub ahead of print).
13. Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J. 2011;10:339.
14. Hien TT, Thuy-Nhien NT, Phu NH, Boni MF, Thanh NV, Nha-Ca NT, et al. In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malar J. 2012;11:355.
15. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411-23.
16. Amaratunga C, Lim P, Suon S, Mao S, Sopha C, Sam B, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016;16:357-65.
17. Nguyen TD, Olliaro P, Dondorp AM, Baird JK, Lam HM, Farrar J, et al. Optimum population-level use of artemisinin combination therapies: a modelling study. Lancet Glob Health. 2015;3:e758-66.
18. Markley JD, Edmond MB. Post-Malaria neurological syndrome: a case report and review of the literature. J Travel Med. 2009;2009(16):424-30.
19. Mizuno Y, Kato Y, Kanagawa S, Kudo K, Hashimoto M, Kunimoto M, et al. A case of postmalaria neurological syndrome in Japan. J Infect Chemother. 2006;12:399-401.
20. Nguyen TH, Day NP, Ly VC, Waller D, Mai NT, Bethell DB, et al. Post-malaria neurological syndrome. Lancet. 1996;348:917-21.
21. Giao PT, Vries DP, Hung L, Binh T, Nam NV, Kager PA. Atovaquone-proguanil for recrudescent Plasmodium falciparum in Vietnam. Ann Trop Med Parasitol. 2003;97:575-80.
22. Saunders DL, Chaorattanakawee S, Gosi P, Lanteri C, Somethy S, Kuntawunginn W, et al. Atovaquone-proguanil remains a potential stopgap therapy for multidrug-resistant Plasmodium falciparum in areas along the Thai-cambodian border. Antimicrob Agents Chemother. 2015;60:1896-8.
23. Maude RJ, Nguon C, Dondorp AM, White LJ, White NJ. The diminishing returns of atovaquone-proguanil for elimination of Plasmodium falciparum malaria: modelling mass drug administration and treatment. Malar J. 2014;13:380.
24. White NJ. Can new treatment developments combat resistance in malaria? Expert Opin Pharmacother. 2016;17:1303-7.